Soleno Therapeutics, Inc.
- SLNO
- NASDAQ
- Biotechnology
- Rare Disease Therapeutics
- Metabolic Disease Drugs
$53.01
Quote May 15, 2026, 08:00 PM UTC
+0.66%over the last month
Max drawdown −0.2%From 1-month high 0.0%3 months +37.7%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Soleno Therapeutics
Soleno Therapeutics, Inc. (SLNO) operates as a clinical-stage biopharmaceutical company, specializing in the creation and market introduction of groundbreaking treatments for uncommon illnesses. The cornerstone of its therapeutic pipeline is Diazoxide Choline Controlled-Release, a once-daily oral tablet aimed at addressing Prader-Willi Syndrome, currently progressing through an active Phase III clinical evaluation.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
115
Market value
$2.76B
Quote May 15
Floor
$52.83
0.3% below price
Resistance
$53.04
0.1% above price
Price vs analyst targets
13 analysts
Lowest target
$53.00Highest target
$125.00
$53.00Highest target
$125.00
- Price $53.01
- Average target $86.30
- Analysts' target range
The price is close to the lowest analyst target. Analysts' average target sits about 63% higher. Their range is wide.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about SLNOPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free